Clinical Trial Update: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating first-line cetuximab-containing regimens (FOLFIRI or FOLFOX) in KRAS wild-type metastatic colorectal cancer; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-05-14